PRESS RELEASE | 15th EGA ANNUAL CONFERENCE | 04 JUNE 2009
NEW! Revised & Updated with Additional Country Data
HOW TO INCREASE PATIENT ACCESS TO GENERIC MEDICINES IN EUROPEAN HEALTHCARE SYSTEMS
A Report by the EGA Health Economics Committee
“EU governments need to ensure fast generic medicines uptake, as market access and low market volume in key EU countries is still a real problem and is having a major negative impact on patient access to more affordable treatments.” This is the key message Greg Perry, director general of the EGA, made at the European Generic medicines Association’s 15th EGA Annual Conference at Barcelona during the launch of a the latest EGA report entitled “How to Increase Patient Access to Generic Medicines in European Healthcare Systems”. More...
“Competitive, Cost-Effective Generic Medicines Struggle to Overcome Major Hurdles”
The key moments and messages from the conferences organised by the EGA during the first half of 2009.
EGA Director General Greg Perry in London today congratulated industry and medicines regulators on the EU’s ‘biosimilar thinking’. “The EU continues to lead worldwide in developing new guidelines and is now taking biosimilar medicines to the next level", he said. More... Greg Perry's Presentation
This presentation to the recent
DIA conference outlines the EGA's full involvement in developing the
new EU pharmaceutical legislation on falsified medicines, pharmacovigilance
and industry information to patients (ITP)
• Julie Marechal-Jamil, Sr Manager Regulatory Affairs, EGA
The EGA welcomes the European Commission’s initiative for a Unified Patent Litigation System, while recommending safeguards to ensure a fairer balance between patent holders and the public interest. More...
“The EGA is the official representative body of the European generic and biosimilar pharmaceutical industry, which is at the forefront of providing high-quality
affordable medicines to millions of Europeans and stimulating competitiveness and innovation in the pharmaceutical sector.”
